SWEDISH ORPHAN BIOVITRUM

Swedish Orphan Biovitrum engages in the development, marketing, and distribution of orphan products and specialty pharmaceuticals. It offers drugs for the treatment of rare and life-threatening diseases, such as cardiology, diseases affecting immunocompromised patients, genetic disorders, haematology, infectious diseases, metabolic disorders, oncology, palliative care, poison control, respiratory diseases, and urology. In 2009, Swedish Orphan International AB merged with [Biovitrum](/organization/biovitrum), and the combined company has subsequently been rebranded as Swedish Orphan Biovitrum. The company markets its products in Europe, North American, and Japan and is headquartered in Stockholm, Sweden.